

November 2025

Growing a life-centered revolution

From LATAM to the world

Confidential deck

GRIDX



A life-centered fund for a life-centered revolution

Over the past decade, we've led the largest and most successful initiative in Latin America, transforming bioscience knowledge into global-impact startups through two funds.

+90 Startups built and Invested

+250 Founders

+75% teams with women founders

1000 People working (700 science)

\$41M AUM across 2 funds




Sourcing in Latam

+6800 Scientific projects mapped

AR, BR, MX, UY Local teams

8 Countries Represented at the portfolio


Leading Initiative in the region



Mexico



800 projects mapped
10 projects invested
Local team

Brazil



2.500 projects mapped
8 projects invested
Local team

Costa Rica



50 projects mapped
2 projects invested
No local team

Uruguay



690 projects mapped
7 projects invested
Local team

Colombia



270 projects mapped
4 projects invested
No local team

Chile



150 projects mapped
4 projects invested
No local team

Paraguay



30 projects mapped
1 projects invested
No local team

Argentina



2.400 projects mapped
57 projects invested
Local team


Building a bridge to the world

+60 VC Investors

+\$130MM Raised by portfolio companies



Leading Initiative in the region



Caspr is living proof that the GRIDX model works. Leading CRISPR scientists from Latin America were matched through the GRIDX process with a young, ambitious, and talented entrepreneur. The result was an Argentine startup that developed CRISPR-based diagnostic technology and scaled globally—competing head-to-head with spin-offs from the world’s top CRISPR research institutes. In just a few years, it reached a successful exit, proving that Latin America can build science-based companies ready to compete on the global stage. Caspr is more than a success story; it’s a precedent that validates our ability to turn research into real, scalable impact.



CASPR

BIOTECH

Biodiversity to transform
diagnostics with CRISPR




 puna.bio

The future of biologicals,
powered by living fossils



Puna Bio is unlocking nature's most extreme biology to transform agriculture. By harnessing microbes from the high-altitude deserts of the Andes—one of the most biodiverse and extreme environments on Earth—the company is creating a new category of ultra-resilient agricultural biotechnology. Their platform boosts crop performance in degraded and stressed soils, offering a scalable solution to a global challenge. Puna recently closed its Series A round led by Corteva, marking the agtech giant's first CVC investment in Latin America—a powerful validation of the region's scientific potential and Puna's world-class technology.



Stämm is redefining what's possible in biomanufacturing. The company developed a globally unique technology that has the potential to forever change how the world approaches fermentation. Through relentless innovation, they've built a proprietary platform that positions them at the forefront of next-generation bioprocessing. With a team of over 250 people and less than USD 40 million in funding—what would have taken hundreds of millions elsewhere—Stämm created a deep tech stack that puts them ahead of global competitors. It's a testament to how breakthrough science, when paired with smart execution, can generate world-class outcomes from Latin America.

Culture media

Inoculum


Cells & product



STÄMM

Infraestructure
for a
life-centered
productive system

Revenue



**Angels, FFF
Seed Capital**

**Venture Capitalists,
Acquisitions/Mergers & Strategic Alliances**

IPO

**Public
Market**

Early Stage

Later Stage

Break even

1st

2nd

3rd


Mezzanine

Secondary Offerings

Valley of Death

Time

Revenue



**Angels, FFF
Seed Capital**

**Venture Capitalists,
Acquisitions/Mergers & Strategic Alliances**

IPO

**Public
Market**

Early Stage

Later Stage

Convertible Notes or
SAFEs

Equity Rounds

Mezzanine

Break even

1st

2nd

3rd

Secondary
Offerings

Valley of Death

Time

Fund I funnel

(assumed)

 GRIDX prediction




Fig. 20. Funnel of startups across valuation stages—showing projected and actual progression through each funding round.

Fund I funnel

(year 7)





Fig. 21. Funnel of startups across valuation stages—showing projected and actual progression through each funding round.

Fund I funnel (year 10 prediction)

-  GRIDX prediction
-  Fund I startups (Y7)
-  Fund I prediction (Y10)




Fig. 22. Funnel of startups across valuation stages—showing projected progression through each funding round.



This presentation has been prepared by GRIDX (the "Company") and is general background information about the Company's activities at the date of this presentation. The information in this presentation is provided in summary form only and does not purport to be complete. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not take into account any investor's particular objectives, financial situation or needs. By attending the presentation or by reading the presentation slides you agree to be bound as follows: This presentation has been made to you solely for information purposes. This presentation may be amended and supplemented as the Company sees fit, may not be relied upon for the purpose of entering into any transaction and should not be construed as, nor be relied on in connection with, any offer or invitation to purchase or subscribe for, underwrite or otherwise acquire, hold or dispose of any securities of the Company, and shall not be regarded as a recommendation in relation to any such transaction whatsoever. The contents of this presentation should not be considered to be legal, tax, investment or other advice, and any investor or prospective investor considering the purchase or disposal of any securities of the Company should consult with its own counsel and advisers as to all legal, tax, regulatory, financial and related matters concerning an investment in or a disposal of such securities and as to their suitability for such investor or prospective investor. This presentation and its contents are confidential and proprietary to the Company, and no part of it or its subject matter may be reproduced, redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (excluding the relevant person's professional advisers) or published in whole or in part for any purpose without the prior written consent of the Company. If this presentation has been received in error it must be returned immediately to the Company. The communication of this presentation may be restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. This presentation is not directed to or intended for distribution, or transfer, either directly or indirectly to, or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.